AstraZeneca Olaparib Shows First Evidence Of PARP In Randomized Ovarian Cancer Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
American Society of Clinical Oncology highlighted Phase II progression-free survival data as being among the most promising research to be presented at its annual meeting in June.